Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Boyer, Michael; ŞENDUR, MEHMET; Rodriguez-Abreu, Delvys; Park, Keunchil; Lee, Dae; ÇİÇİN, İRFAN; YUMUK, PERRAN; Orlandi, Francisco; Leal, Ticiana; Molinier, Olivier; Soparattanapaisarn, Nopadol; Langleben, Adrian; Califano, Raffaele; Medgyasszay, Balazs; Hsia, Te-Chun; Otterson, Gregory; Xu, Lu; Piperdi, Bilal; Samkari, Ayman; Reck, Martin

doi:10.1200/jco.20.03579

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Boyer M., ŞENDUR M. A. N., Rodriguez-Abreu D., Park K., Lee D. H., ÇİÇİN İ., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.21, pp.2327-2348, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 39 Issue: 21
Publication Date: 2021
Doi Number: 10.1200/jco.20.03579
Journal Name: JOURNAL OF CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
Page Numbers: pp.2327-2348
Marmara University Affiliated: Yes

Abstract

PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) >= 50% without actionable driver mutations. It is not known whether adding ipilimumab to pembrolizumab improves efficacy over pembrolizumab alone in this population.